Search Thermo Fisher Scientific
- Order Status
- Quick Order
-
Don't have an account ? Create Account
Oncology Clinical Research Solutions for the Genexus System
Next-generation solution for genomic profiling
Oncomine Solutions on the Ion Torrent Genexus System feature a complete next-generation sequencing (NGS) testing workflow. Now every lab can advance from biological specimen to report in a single day, providing a comprehensive genomic profile at a speed never possible before. This allows you to deliver NGS results at the same time as other single-gene methods such as immunohistochemistry (IHC).
The hands-off, set-up-and-go workflow makes NGS accessible even if your lab is new to the technology. With the lowest sample input requirement of any NGS solution, you can successfully sequence more of the samples that come through your lab.
Oncomine assays for the Genexus System
Oncomine Precision Assay
The Oncomine Precision Assay features carefully curated biomarker content spanning 50 genes. Enhanced fusion detection provides broad coverage for the most prevalent isoforms, along with novel fusions. You have the option to profile DNA or RNA from lysate or plasma, giving you a wide range of utility. All of this is provided with a single-day turnaround time and a highly automated workflow on the Genexus System.
Don’t let precious samples go untested
Did you know that some NGS send-out labs have test failure rates of 20% due to their high input requirement (1-4)? At that rate, one out of every five samples submitted will not pass due to lack of tissue, and many more are never submitted for testing at all. Not with Oncomine Solutions. You can experience a sequencing success rate of over 95% because we only require 10 ng of nucleic acid input. This means you can get an NGS result for most of the precious samples you have.
Maximize your ability to detect key biomarkers
Curated pan-cancer content
FusionSyncTM detection technology
Molecular tagging
Tissue and plasma samples
- Mutation, CNV, and fusion variant types across 50 key genes
- Tumor suppressors, driver and resistance variants
- Sensitive and specific—targeted isoform designs
- Novel fusion detection
- Enhanced low-level variant detection
- Key for liquid biopsy testing
- One test, one workflow, multiple sample types
- Maximizes the number of tumors that can be profiled
All you need to know about Oncomine Precision Assay in 30 seconds: download the infographic ›
FusionSync detection technology
Gene fusions are an increasingly important target in precision oncology. Oncomine assays are superior for both sequencing success rate and sensitivity, two critical factors for fusion detection. Even when tissue is very limited or the variants exist at low levels in the sample, you can detect key fusions by combining:
- Targeted known fusion detection
- Non-targeted detection of novel fusion combinations
- Novel fusion detection
Explore our free educational resources
OncomineWorld 2022: A Virtual NGS Education Meeting
Free & on-demand
Now in its fourth iteration, OncomineWorld is back with new presentations. Attend on-demand talks with Q&A, covering topics such as genomic profiling in solid tumors and hemato-oncology research, the IVDR transition, the latest advances in NGS workflows, and much more. In addition to general NGS education topics and updates, this year’s event also featured content dedicated to labs that are new to or considering starting with NGS. Register now to see all of the exciting new event features on demand.
Genexus System on-demand webinar series
The Genexus System helps enable a broad spectrum of labs, even without previous expertise, to provide fast genomic profiling. In this five-part webinar series, hear from our leaders how the Genexus System is addressing key challenges with NGS, and watch as customers share their experiences using the Genexus System together with the Oncomine Precision Assay for a one-day, hands-off workflow with only two touchpoints and 20 minutes of hands-on time. You can also learn about FusionSync™ technology and the importance of detecting both novel fusions and known driver genes and partners.
References:
1. Davis W, et al. Next-Generation Sequencing in 305 Consecutive Patients: Clinical Outcomes and Management Changes. J Oncol Pract. 2019 Aug 2:JOP1900269.
2. Ready N, et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J Clin Oncol. 2019 Apr 20;37(12):992-1000.
3. Zhu J, et al. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urol Oncol. 2019 Jul 18. pii: S1078-1439(19)30244-3.
4. Heeke S, et al. Abstract 4889: Comparison of tumor mutational burden using the Ion Oncomine TML and FoundationOne assays with routine clinical FFPE tissue samples to predict durable clinical benefit in lung cancer and melanoma patients - a multivariate analysis integrating PD-L1 and CD8+ evaluation. Proceedings: AACR Annual Meeting 2019. DOI: 10.1158/1538-7445.AM2019-4889.
For Research Use Only. Not for use in diagnostic procedures.